About the second approach, that aims to target fibronectin clearance, it has been demonstrated that matrix metalloproteinase-7 (MMP7), a protease involved in ECM remodeling which is typically down-regulated in MS active and chronic lesions, is able to cleave aggregated fibronectin enhancing its clearance [86]. This evidence concerns the gene FN1 and myeloid sarcoma.